
Source: [[PDFs/SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020.pdf]]

---

###### Page 1

# **Attention Deficit Disorder (ADD) / Attention** **Deficit Hyperactivity Disorder (ADHD)** **Clinical Edit Criteria**  

![SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_1_96](Generated/images/SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_1_96.png)

## **SuperiorHealthPlan.com**  Page **1**  of **42** SHP_20205921 

## **Drug/Drug Class**  **Attention Deficit Disorder (ADD) / Attention**  

# **Deficit Hyperactivity Disorder (ADHD)** **Medications** 

### Superior HealthPlan  follows the guidance of the Texas Vendor Drug Program (VDP) for 

### all clinical edit criteria. This clinical edit criteria applies to all Superior HealthPlan STAR, 

### STAR Health, STAR Kids, STAR+PLUS and CHIP members. Superior has adjusted the 

### clinical criteri a to ease the prior authorization process regarding this clinical edit. The age 

### limit for all immediate release and extended release stimulants has been changed from 6 years of age to 3 years of age and step 6 of the immediate release criteria screening for 

### specific products has been removed.. Adjusted criteria steps are outlined/highlighted in 

### yellow. 

### The original clinical edit can be referenced at the Texas Vendor Drug Program website located at: https://paxpress.txpa.hidinc.com/add_adhd_agents_pending_pdf.pdf

### **Clinical Edit** **information included in this d** **ocument** **:**  

### •  Drugs included in the edit: List of medications included in this clinical edit logic. 

### •  Logic diagram: Visual depiction of the clinical edit criteria logic, per drug 

### formulation . 

### •  Supporting tables: List of diagnosis codes or drug information and additional step 

### logic, claims and look-back period information.  

### •  Clinical edit references: Clinical edit references as provided by Texas Vendor 

### Drug. 

### •  Publication history: Review when the eased criteria was put into production and 

### any updates since this time. 

### ***Please note:*** ***All tables are provided by original Texas Vendor Drug Program*** 

### ***ADD/ADHD Medications*** ***Edit.***  


---

###### Page 2

Page **2**  of **42** 



## **Drugs Requiring Prior Authorization-** **IR Formulations:** The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search. 



**Drugs Requiring Prior Authorization** **Label Name** **GCN** ADDERALL 10MG TABLET 56971 ADDERALL 12.5MG TABLET 29008 ADDERALL 15MG TABLET 29009 ADDERALL 20MG TABLET 56973 ADDERALL 30MG TABLET 56972 ADDERALL 5MG TABLET 56970 ADDERALL 7.5MG TABLET 29007 AMPHETAMINE SULFATE 5MG TABLET 

### 19822 AMPHETAMINE SULFATE 10MG TABLET 

### 19821 AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG TABLET 

### 56971  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 12.5MG TABLET 

### 29008  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG TABLET 

### 29009  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG TABLET 

### 56973  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG TABLET 

### 56972  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG TABLET 

### 56970  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 7.5MG TABLET 

29007  DESOXYN 5MG TABLET 19932 DEXMETHYLPHENIDATE

10MG TABLET 14975 DEXMETHYLPHENIDATE 2.5MG TABLET 14973 DEXMETHYLPHENIDATE 5MG TABLET 14974 DEXTROAMPHETAMINE 10MG TABLET 19880 DEXTROAMPHETAMINE 5MG TABLET 19881 DEXTROAMPHETAMINE

5MG/5ML SOLUTION 99801 EVEKEO 10MG TABLET 19821 EVEKEO 5MG TABLET 19822 EVEKEO ODT 10MG 45977 EVEKEO ODT 15MG 45978 EVEKEO ODT 20MG 45979 



 


---

###### Page 3

Page **3**  of **42** 



**Drug** **Requiring** **Prior** **Authorization** **Label** **Name** **GCN**  EVEKEO ODT 5MG 45976 FOCALIN 10MG TABLET 14975 FOCALIN 2.5MG TABLET 14973 FOCALIN 5MG TABLET 14974 METHAMPHETAMINE 5MG TABLET 19932 METHYLIN 10MG/5ML SOLUTION 22686 METHYLIN 5MG/5ML SOLUTION 22685 METHYLPHENIDATE 10 MG CHEW TB 22684 METHYLPHENIDATE 10MG TABLET 15911 METHYLPHENIDATE 10MG/5ML SOL 22686 METHYLPHENIDATE 2.5 MG CHEW TB 22682 METHYLPHENIDATE

20MG TABLET 15920 METHYLPHENIDATE 5 MG CHEW TB 22683 METHYLPHENIDATE 5MG TABLET 15913 METHYLPHENIDATE 5MG/5ML SOL 22685 PROCENTRA 5MG/5ML SOLUTION 99801 RITALIN 10MG TABLET 15911 RITALIN 20MG TABLET 15920 RITALIN 5MG TABLET 15913 ZENZEDI 10MG TABLET 19880 ZENZEDI 15MG TABLET 19885 ZENZEDI 2.5MG TABLET 34734 ZENZEDI 20MG TABLET 36463 ZENZEDI 30MG TABLET 36464 ZENZEDI 5MG TABLET 19881 ZENZEDI 7.5MG TABLET 34735 


---

###### Page 4

Page **4**  of **42**  



## **Superior HealthPlan** **Clinical Edit Logic Diagram-** **IR Formulations:**

![SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_4_86](Generated/images/SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_4_86.png)


---

###### Page 5

Page **5**  of **42**  



##### **Supporting Tables-** **ADD/ADHD IR Formulation** **Step Logic:**  





**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** **ICD-10** **Code** **Description** **F1010** **ALCOHOL** **ABUSE** **UNCOMPLICATED** **F10120** **ALCOHOL** **ABUSE** **WITH** **INTOXICATION** **UNCOMPLICATED** **F10121** **ALCOHOL** **ABUSE** **WITH** **INTOXICATION** **DELIRIUM** **F10129** **ALCOHOL** **ABUSE** **WITH** **INTOXICATION** **UNSPECIFIED** **F1014** **ALCOHOL** **ABUSE** **WITH** **ALCOHOL-INDUCED** **MOOD** **DISORDER** **F10150** **ALCOHOL** **ABUSE** **WITH** **ALCOHOL-INDUCED** **PSYCHOTIC** **DISORDER** 

### **WITH** **DELUSIONS** **F10151** **ALCOHOL** **ABUSE** **WITH** **ALCOHOL-INDUCED** **PSYCHOTIC** **DISORDER** 

### **WITH** **HALLUCINATIONS** **F10159** **ALCOHOL** **ABUSE** **WITH** **ALCOHOL-INDUCED** **PSYCHOTIC** **DISORDER** 

### **UNSPECIFIED** **F10180** **ALCOHOL** **ABUSE** **WITH** **ALCOHOL-INDUCED** **ANXIETY** **DISORDER** **F10181** **ALCOHOL** **ABUSE** **WITH** **ALCOHOL-INDUCED** **SEXUAL** **DYSFUNCTION** **F10182** **ALCOHOL** **ABUSE** **WITH** **ALCOHOL-INDUCED** **SLEEP** **DISORDER** **F10188** **ALCOHOL** **ABUSE** **WITH** **OTHER** **ALCOHOL-INDUCED** **DISORDER** **F1019** **ALCOHOL** **ABUSE** **WITH** **UNSPECIFIED** **ALCOHOL-INDUCED** **DISORDER** **F1020** **ALCOHOL** **DEPENDENCE** **UNCOMPLICATED** **F10220** **ALCOHOL** **DEPENDENCE** **WITH** **INTOXICATION** **UNCOMPLICATED** **F10221** **ALCOHOL** **DEPENDENCE** **WITH** **INTOXICATION** **DELIRIUM** **F10229** **ALCOHOL** **DEPENDENCE** **WITH** **INTOXICATION** **UNSPECIFIED** **F10230** **ALCOHOL** **DEPENDENCE** **WITH** **WITHDRAWAL** **UNCOMPLICATED** **F10231** **ALCOHOL** **DEPENDENCE** **WITH** **WITHDRAWAL** **DELIRIUM** **F10232** **ALCOHOL** **DEPENDENCE** **WITH** **WITHDRAWAL** **WITH** **PERCEPTUAL** 

**DISTURBANCE** **F10239** **ALCOHOL** **DEPENDENCE** **WITH** **WITHDRAWAL** **UNSPECIFIED** **F1024** **ALCOHOL** **DEPENDENCE** **WITH** **ALCOHOL-INDUCED** **MOOD** **DISORDER** 



 


---

###### Page 6

Page **6**  of **42**  



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F10250 ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC 

### DISORDER WITH DELUSIONS F10251 ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC 

### DISORDER WITH HALLUCINATIONS F10259 ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC 

### DISORDER UNSPECIFIED F1026 ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING 

### AMNESTIC DISORDER F1027 ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING 

### DEMENTIA F10280 ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED ANXIETY 

### DISORDER F10281 ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SEXUAL 

### DYSFUNCTION  F10282 ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SLEEP DISORDER F10288 ALCOHOL DEPENDENCE WITH OTHER ALCOHOL-INDUCED DISORDER F1029 ALCOHOL DEPENDENCE WITH UNSPECIFIED ALCOHOL-INDUCED 

### DISORDER F1110 OPIOID ABUSE UNCOMPLICATED F11120 OPIOID ABUSE WITH INTOXICATION UNCOMPLICATED F11121 OPIOID ABUSE WITH INTOXICATION DELIRIUM F11122 OPIOID ABUSE WITH INTOXICATION WITH PERCEPTUAL 

### DISTURBANCE F11129 OPIOID ABUSE WITH INTOXICATION UNSPECIFIED F1114 OPIOID ABUSE WITH OPIOID-INDUCED MOOD DISORDER F11150 OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH 

### DELUSIONS F11151 OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH 

### HALLUCINATIONS F11159 OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER 

UNSPECIFIED F11181 OPIOID ABUSE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION F11182 OPIOID ABUSE WITH OPIOID-INDUCED SLEEP DISORDER F11188 OPIOID ABUSE WITH OTHER OPIOID-INDUCED DISORDER F1119 OPIOID ABUSE WITH UNSPECIFIED OPIOID-INDUCED DISORDER F1120 OPIOID DEPENDENCE, UNCOMPLICATED F1121 OPIOID DEPENDENCE, IN REMISSION F11220 OPIOID DEPENDENCE WITH INTOXICATION UNCOMPLICATED F11221 OPIOID DEPENDENCE WITH INTOXICATION DELIRIUM 

 


---

###### Page 7

Page **7**  of **42**  



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F11222 OPIOID DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL 

### DISTURBANCE F11229 OPIOID DEPENDENCE WITH INTOXICATION UNSPECIFIED F1123 OPIOID DEPENDENCE WITH WITHDRAWAL F1124 OPIOID DEPENDENCE WITH OPIOID-INDUCED MOOD DISORDER F11250 OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC 

### DISORDER WITH DELUSIONS F11251 OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC 

### DISORDER  WITH HALLUCINATIONS F11259 OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC 

### DISORDER UNSPECIFIED F11281 OPIOID DEPENDENCE WITH OPIOID-INDUCED SEXUAL 

### DYSFUNCTION  F11282 OPIOID DEPENDENCE WITH OPIOID-INDUCED SLEEP DISORDER F11288 OPIOID DEPENDENCE WITH OTHER OPIOID-INDUCED DISORDER F1129 OPIOID DEPENDENCE WITH UNSPECIFIED OPIOID-INDUCED 

### DISORDER F1210 CANNABIS ABUSE UNCOMPLICATED F12120 CANNABIS ABUSE WITH INTOXICATION UNCOMPLICATED F12121 CANNABIS ABUSE WITH INTOXICATION DELIRIUM F12122 CANNABIS ABUSE WITH INTOXICATION WITH PERCEPTUAL 

### DISTURBANCE F12129 CANNABIS ABUSE WITH INTOXICATION UNSPECIFIED F12150 CANNABIS ABUSE WITH PSYCHOTIC DISORDER WITH DELUSIONS F12151 CANNABIS ABUSE WITH PSYCHOTIC DISORDER WITH 

### HALLUCINATIONS F12159 CANNABIS ABUSE WITH PSYCHOTIC DISORDER UNSPECIFIED F12180 CANNABIS ABUSE WITH CANNABIS-INDUCED ANXIETY DISORDER F12188 CANNABIS ABUSE WITH OTHER CANNABIS-INDUCED DISORDER F1219 CANNABIS ABUSE WITH UNSPECIFIED CANNABIS-INDUCED 

### DISORDER F1220 CANNABIS DEPENDENCE, UNCOMPLICATED F1221 CANNABIS DEPENDENCE, IN REMISSION F12220 CANNABIS DEPENDENCE WITH INTOXICATION UNCOMPLICATED F12221 CANNABIS DEPENDENCE WITH INTOXICATION DELIRIUM F12222 CANNABIS DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL 

### DISTURBANCE F12229 CANNABIS DEPENDENCE WITH INTOXICATION UNSPECIFIED F12250 CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH 

DELUSIONS 

<sup></sup> 


---

###### Page 8

Page **8**  of **42**  



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F12251 CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH 

### HALLUCINATIONS F12259 CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER UNSPECIFIED F12280 CANNABIS DEPENDENCE WITH CANNABIS-INDUCED ANXIETY 

### DISORDER F12288 CANNABIS DEPENDENCE WITH OTHER CANNABIS-INDUCED 

### DISORDER F1229 CANNABIS DEPENDENCE WITH UNSPECIFIED CANNABIS-INDUCED 

### DISORDER F1310 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, UNCOMPLICATED F13120 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION 

### UNCOMPLICATED F13121 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION 

### DELIRIUM F13129 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION 

### UNSPECIFIED F1314 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, 

### HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, 

### HYPNOTIC  OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, 

### HYPNOTIC  OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, 

### HYPNOTIC  OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, 

### HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, 

### HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, 

### HYPNOTIC  OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE 

### UNCOMPLICATED  F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE IN REMISSION F13220 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### INTOXICATION UNCOMPLICATED F13221 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

INTOXICATION DELIRIUM 




---

###### Page 9

Page **9**  of **42**  



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F13229 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### INTOXICATION, UNSPECIFIED F13230 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### WITHDRAWAL UNCOMPLICATED F13231 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### WITHDRAWAL DELIRIUM F13232 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F13239 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### WITHDRAWAL UNSPECIFIED F1324 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, 

### HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER F13250 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER

UNCOMPLICATED F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13259 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F1326 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING AMNESTIC DISORDER F1327 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING DEMENTIA F13280 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, 

### HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13281 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13282 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13288 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH OTHER 

### SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1329 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH 

### UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1410 COCAINE ABUSE UNCOMPLICATED F14120 COCAINE ABUSE WITH INTOXICATION UNCOMPLICATED F14121 COCAINE ABUSE WITH INTOXICATION WITH DELIRIUM F14122 COCAINE ABUSE WITH INTOXICATION WITH PERCEPTUAL 

DISTURBANCE 




---

###### Page 10

Page **10**  of **42** 



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F14129 COCAINE ABUSE WITH INTOXICATION UNSPECIFIED F1414 COCAINE ABUSE WITH COCAINE-INDUCED MOOD DISORDER F14150 COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER 

### WITH DELUSIONS F14151 COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER 

### WITH HALLUCINATIONS F14159 COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER 

### UNSPECIFIED F14180 COCAINE ABUSE WITH COCAINE-INDUCED ANXIETY DISORDER F14181 COCAINE ABUSE WITH COCAINE-INDUCED SEXUAL DYSFUNCTION F14182 COCAINE ABUSE WITH COCAINE-INDUCED SLEEP DISORDER F14188 COCAINE ABUSE WITH OTHER COCAINE-INDUCED DISORDER F1419 COCAINE ABUSE WITH UNSPECIFIED COCAINE-INDUCED DISORDER F1420 COCAINE DEPENDENCE UNCOMPLICATED F14220 COCAINE DEPENDENCE WITH INTOXICATION UNCOMPLICATED F14221 COCAINE DEPENDENCE WITH INTOXICATION DELIRIUM F14222 COCAINE DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL 

### DISTURBANCE F14229 COCAINE DEPENDENCE WITH INTOXICATION UNSPECIFIED F1423 COCAINE DEPENDENCE WITH WITHDRAWAL F1424 COCAINE DEPENDENCE WITH COCAINE-INDUCED MOOD DISORDER F14250 COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC 

### DISORDER WITH DELUSIONS F14251 COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC 

### DISORDER  WITH HALLUCINATIONS F14259 COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC 

### DISORDER UNSPECIFIED F14280 COCAINE DEPENDENCE WITH COCAINE-INDUCED ANXIETY 

### DISORDER F14281 COCAINE DEPENDENCE WITH COCAINE-INDUCED SEXUAL 

### DYSFUNCTION  F14282 COCAINE DEPENDENCE WITH COCAINE-INDUCED SLEEP DISORDER F14288 COCAINE DEPENDENCE WITH OTHER COCAINE-INDUCED DISORDER F1429 COCAINE DEPENDENCE WITH UNSPECIFIED COCAINE-INDUCED 

### DISORDER F1510 OTHER STIMULANT ABUSE UNCOMPLICATED F15120 OTHER STIMULANT ABUSE WITH INTOXICATION UNCOMPLICATED F15121 OTHER STIMULANT ABUSE WITH INTOXICATION DELIRIUM F15122 OTHER STIMULANT ABUSE WITH INTOXICATION WITH PERCEPTUAL 

DISTURBANCE 




---

###### Page 11

Page **11**  of **42** 



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F15129 OTHER STIMULANT ABUSE WITH INTOXICATION UNSPECIFIED F1514 OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED MOOD 

### DISORDER F15150 OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC 

### DISORDER WITH DELUSIONS F15151 OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC 

### DISORDER WITH HALLUCINATIONS F15159 OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC 

### DISORDER UNSPECIFIED F15180 OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED ANXIETY 

### DISORDER F15181 OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED SEXUAL 

### DYSFUNCTION F15182 OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED SLEEP 

### DISORDER F15188 OTHER STIMULANT ABUSE WITH OTHER STIMULANT-INDUCED 

### DISORDER F1519 OTHER STIMULANT ABUSE WITH UNSPECIFIED STIMULANT-INDUCED 

### DISORDER F1520 OTHER STIMULANT DEPENDENCE UNCOMPLICATED F15220 OTHER STIMULANT DEPENDENCE WITH INTOXICATION 

### UNCOMPLICATED  F15221 OTHER STIMULANT DEPENDENCE WITH INTOXICATION DELIRIUM F15222 OTHER STIMULANT DEPENDENCE WITH INTOXICATION WITH 

### PERCEPTUAL DISTURBANCE F15229 OTHER STIMULANT DEPENDENCE WITH INTOXICATION UNSPECIFIED F1523 OTHER STIMULANT DEPENDENCE WITH WITHDRAWAL F1524 OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED MOOD 

### DISORDER F15250 OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED 

### PSYCHOTIC DISORDER WITH DELUSIONS F15251 OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED 

### PSYCHOTIC DISORDER WITH HALLUCINATIONS F15259 OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED 

### PSYCHOTIC DISORDER UNSPECIFIED F15280 OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED 

### ANXIETY DISORDER F15281 OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED 

### SEXUAL DYSFUNCTION F15282 OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED SLEEP 

### DISORDER F15288 OTHER STIMULANT DEPENDENCE WITH OTHER STIMULANT-INDUCED 

DISORDER 




---

###### Page 12

Page **12**  of **42** 



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F1529 OTHER STIMULANT DEPENDENCE WITH UNSPECIFIED STIMULANT- 

### INDUCED DISORDER F1610 HALLUCINOGEN ABUSE UNCOMPLICATED F16120 HALLUCINOGEN ABUSE WITH INTOXICATION UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL 

### DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD 

### DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC 

### DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC 

### DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC 

### DISORDER UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY 

### DISORDER F16183 HALLUCINOGEN ABUSE WITH HALLUCINOGEN PERSISTING 

### PERCEPTION DISORDER (FLASHBACKS) F16188 HALLUCINOGEN ABUSE WITH OTHER HALLUCINOGEN-INDUCED 

### DISORDER F1619 HALLUCINOGEN ABUSE WITH UNSPECIFIED HALLUCINOGEN- 

### INDUCED  DISORDER F1620 HALLUCINOGEN DEPENDENCE UNCOMPLICATED F16220 HALLUCINOGEN DEPENDENCE WITH INTOXICATION 

### UNCOMPLICATED F16221 HALLUCINOGEN DEPENDENCE WITH INTOXICATION WITH DELIRIUM F16229 HALLUCINOGEN DEPENDENCE WITH INTOXICATION UNSPECIFIED F1624 HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED 

### MOOD DISORDER F16250 HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED 

### PSYCHOTIC DISORDER WITH DELUSIONS F16251 HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED 

### PSYCHOTIC DISORDER WITH HALLUCINATIONS F16259 HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED 

### PSYCHOTIC DISORDER UNSPECIFIED F16280 HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED 

### ANXIETY DISORDER F16283 HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN PERSISTING 

### PERCEPTION DISORDER (FLASHBACKS) F16288 HALLUCINOGEN DEPENDENCE WITH OTHER HALLUCINOGEN- 

INDUCED  DISORDER 




---

###### Page 13

Page **13**  of **42** 



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F1629 HALLUCINOGEN DEPENDENCE WITH UNSPECIFIED HALLUCINOGEN- 

### INDUCED DISORDER F1810 INHALANT ABUSE UNCOMPLICATED F18120 INHALANT ABUSE WITH INTOXICATION UNCOMPLICATED F18121 INHALANT ABUSE WITH INTOXICATION DELIRIUM F18129 INHALANT ABUSE WITH INTOXICATION UNSPECIFIED F1814 INHALANT ABUSE WITH INHALANT-INDUCED MOOD DISORDER F18150 INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER 

### WITH DELUSIONS F18151 INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER 

### WITH HALLUCINATIONS F18159 INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER 

### UNSPECIFIED F1817 INHALANT ABUSE WITH INHALANT-INDUCED DEMENTIA F18180 INHALANT ABUSE WITH INHALANT-INDUCED ANXIETY DISORDER F18188 INHALANT ABUSE WITH OTHER INHALANT-INDUCED DISORDER F1819 INHALANT ABUSE WITH UNSPECIFIED INHALANT-INDUCED 

### DISORDER F1820 INHALANT DEPENDENCE, UNCOMPLICATED F18220 INHALANT DEPENDENCE WITH INTOXICATION UNCOMPLICATED F18221 INHALANT DEPENDENCE WITH INTOXICATION DELIRIUM F18229 INHALANT DEPENDENCE WITH INTOXICATION UNSPECIFIED F1824 INHALANT DEPENDENCE WITH INHALANT-INDUCED MOOD 

### DISORDER F18250 INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC 

### DISORDER WITH DELUSIONS F18251 INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC 

### DISORDER  WITH HALLUCINATIONS F18259 INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC 

### DISORDER, UNSPECIFIED F1827 INHALANT DEPENDENCE WITH INHALANT-INDUCED DEMENTIA F18280 INHALANT DEPENDENCE WITH INHALANT-INDUCED ANXIETY 

### DISORDER F18288 INHALANT DEPENDENCE WITH OTHER INHALANT-INDUCED 

### DISORDER F1829 INHALANT DEPENDENCE WITH UNSPECIFIED INHALANT-INDUCED 

### DISORDER F1910 OTHER PSYCHOACTIVE SUBSTANCE ABUSE UNCOMPLICATED F19120 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION 

UNCOMPLICATED 



 


---

###### Page 14

Page **14**  of **42** 



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F19121 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION 

### DELIRIUM F19122 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION 

### WITH PERCEPTUAL DISTURBANCES F19129 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION 

### UNSPECIFIED F1914 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE 

### SUBSTANCE-INDUCED MOOD DISORDER F19150 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE 

### SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F19151 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE 

### SUBSTANCE -INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F19159 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE 

### SUBSTANCE-INDUCED PSYCHOTIC DISORDER UNSPECIFIED F1916 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE 

### SUBSTANCE-INDUCED PERSISTING AMNESTIC DISORDER F1917 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE 

### SUBSTANCE-INDUCED PERSISTING DEMENTIA F19180 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE 

### SUBSTANCE-INDUCED ANXIETY DISORDER F19181 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE 

### SUBSTANCE-INDUCED SEXUAL DYSFUNCTION F19182 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE 

### SUBSTANCE-INDUCED SLEEP DISORDER F19188 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH OTHER 

### PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER F1919 OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH UNSPECIFIED 

### PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER F1920 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE UNCOMPLICATED F19220 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### INTOXICATION,  UNCOMPLICATED F19221 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### INTOXICATION DELIRIUM F19222 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### INTOXICATION WITH PERCEPTUAL DISTURBANCE F19229 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### INTOXICATION UNSPECIFIED F19230 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### WITHDRAWAL UNCOMPLICATED F19231 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### WITHDRAWAL DELIRIUM F19232 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F19239 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

WITHDRAWAL UNSPECIFIED 




---

###### Page 15

Page **15**  of **42** 



**Step**  **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *365* *days* **History** **of** **Substance** **Abuse** **Diagnoses** F1924 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### PSYCHOACTIVE SUBSTANCE-INDUCED MOOD DISORDER F19250 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### PSYCHOACTIVE  SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F19251 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### PSYCHOACTIVE  SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F19259 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### PSYCHOACTIVE  SUBSTANCE-INDUCED PSYCHOTIC DISORDER UNSPECIFIED F1926 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING AMNESTIC DISORDER F1927 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING DEMENTIA F19280 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### PSYCHOACTIVE  SUBSTANCE-INDUCED ANXIETY DISORDER F19281 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### PSYCHOACTIVE SUBSTANCE-INDUCED SEXUAL DYSFUNCTION F19282 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

### PSYCHOACTIVE  SUBSTANCE-INDUCED SLEEP DISORDER F19288 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH OTHER 

### PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER F1929 OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH 

UNSPECIFIED PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER 




---

###### Page 16

Page **16**  of **42** 



**Step** **3** **(Texas** **DFPS** **maximum** **recommended** **dose)** **Required** **quantity:** *1* 

**TX**  **DFPS** **Recommended** **Dosage** 

**Active** **Ingredient** 

**Drug** **(brand)** 

### AMPHETAMINE/ DEXTROAMPHETAMINE

SALTS 

40mg/day  



### *DEXMETHYLPHENIDATE* 

> *FOCALIN<sup>® </sup>* 

### *DEXTROAMPHETAMINE* 

### *METHAMPHETAMINE* 

> *DESOXYN<sup>® </sup>* 

*25mg/day*  



### *METHYLPHENIDATE* 

**Initial** **Dosage** 

*5mg* *daily* 

*Literature* *Based* *Maximum* *Dosage* 

Age ≥ 6 years (≤ 50kg): 

40mg/day 

Age ≥ 6 years (> 50kg): 

60mg/day 

AMPHETAMINE SULFATE EVEKEO® Age 3-5 years: 2.5-5mg/day 

40mg/day 

### > EVEKEO ODT® 

Ages 6 -17 years: 

40mg/day 

Age ≥  6 years: 

50mg/day 

> *DEXEDRINE<sup>®</sup>* *ZENZEDI<sup>® </sup>* *PROCENTRA<sup>® </sup>* 

Age ≥ 6 years (≤ 50kg): 

40mg/day 

### *N/A*  

*RITALIN<sup>® </sup>* *METHYLIN<sup>® </sup>* 

60mg/day 

Age ≥ 6 years (> 50kg): 

100mg/day 

**FDA**  **Approved** **Maximum** **Dosage** **for** **Children** **and** **Adolescents** 

ADDERALL<sup>®  </sup> Age  3-5 years: 2.5mg/day  

Age  ≥ 6 years: 5-10mg/day 

Age 3 -5 years: 30mg/day 

Approved  for children 

3  years and older:  

40mg/day  

Age ≥ 6 years: 5-10mg/day 

Age ≥3 years: 40mg/day Approved for children 3 years and older: 

Age ≥ 6 years: 5mg/day 

Ages 6 - 17 years: 

*Age* ≥ 6 years: 2.5mg twice daily 

Approved  for children 

6  years and older:  

20mg/day  

*Age*  *3-5* *years:* *2.5mg/day* *Age* ≥ 6 years: 5mg /day  

Age  3 -5 years: 30mg/day 

Age ≥ 6 years (> 50kg): 60mg/day 

Approved  for children 

3  years and  older:  

40mg/day  

*Approved* *for* *children* 

*6*  *years* *and*  *older:*  

*Age*  *3-5* *years:* *2.5mg* *twice* *daily* *Age* ≥ 6 years: 5mg twice daily 

Age 3-5 years: 22.5mg/day Age ≥ 6 years (≤ 50kg): 

Approved  for children 

6  years and older:  

60mg/day  


---

###### Page 17

Page **17**  of **42** 



**Step** **4** **(paid** **claim** **for** **another** **IR** **stimulant)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *14* *days* 

**IR**  **Stimulants** **Label** **Name** **GCN**  ADDERALL 10MG TABLET 56971 ADDERALL 12.5MG TABLET 29008 ADDERALL 15MG TABLET 29009 ADDERALL 20MG TABLET 56973 ADDERALL 30MG TABLET 56972 ADDERALL 5MG TABLET 56970 ADDERALL 7.5MG TABLET 29007 AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG TABLET 

### 56971  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 12.5MG TABLET 

### 29008  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG TABLET 

### 29009  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG TABLET 

### 56973  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG TABLET 

### 56972  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG TABLET 

### 56970  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 7.5MG TABLET 

29007  DESOXYN 5MG TABLET 19932 DEXMETHYLPHENIDATE 10MG TABLET 14975 DEXMETHYLPHENIDATE 2.5MG TABLET 14973 DEXMETHYLPHENIDATE 5MG TABLET 14974 DEXTROAMPHETAMINE 10MG TABLET 19880 DEXTROAMPHETAMINE 5MG TABLET 19881 DEXTROAMPHETAMINE 5MG/5ML 99801 EVEKEO 10MG TABLET 19821 EVEKEO 5MG TABLET 19822 EVEKEO ODT 10MG 45977 EVEKEO ODT 15MG 45978 EVEKEO ODT 20MG 45979 EVEKEO ODT 5MG 45976 FOCALIN 10MG TABLET 14975 FOCALIN 2.5MG TABLET 14973 FOCALIN 5MG TABLET 14974 METHAMPHETAMINE 5MG TABLET 19932 



 


---

###### Page 18

Page **18**  of **42** 



**Step** **4** **(paid** **claim** **for** **another** **IR** **stimulant)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *14* *days* 

**IR**  **Stimulants** **Label** **Name** **GCN**  METHYLIN 10MG/5ML SOLUTION 22686 METHYLIN 5MG/5ML SOLUTION 22685 METHYLPHENIDATE 10 MG CHEW TB 22684 METHYLPHENIDATE 10MG TABLET 15911 METHYLPHENIDATE 10MG/5ML 22686 METHYLPHENIDATE 2.5 MG CHEW TB 22682 METHYLPHENIDATE 20MG TABLET 15920 METHYLPHENIDATE 5 MG CHEW TB 22683 METHYLPHENIDATE 5MG TABLET 15913 METHYLPHENIDATE 5MG/5ML SOLUTION 22685 PROCENTRA 5MG/5ML SOLUTION 99801 RITALIN 10MG TABLET 15911 RITALIN 20MG TABLET 15920 RITALIN 5MG TABLET 15913 ZENZEDI 10MG TABLET 19880 ZENZEDI 15MG TABLET 19885 ZENZEDI 2.5MG TABLET 34734 ZENZEDI 20MG TABLET 36463 ZENZEDI 30MG TABLET 36464 ZENZEDI 5MG TABLET 19881 ZENZEDI 7.5MG TABLET 34735 



**Step** **6** **(amphetamine** **salts** **immediate** **release** **tablets,** **dextroamphetamine** **immediate** **release** 

**tablets,** **dexmethylphenidate,** **methylphenidate,** **Procentra,** **or** **Zenzedi)**  

**Required** **quantity:** *1* 

**Label** **Name** **GCN**  ADDERALL 10MG TABLET 56971 ADDERALL 12.5MG TABLET 29008 ADDERALL 15MG TABLET 29009 ADDERALL 20MG TABLET 56973 ADDERALL 30MG TABLET 56972 ADDERALL 5MG TABLET 56970 ADDERALL 7.5MG TABLET 29007 AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG TABLET 

56971  


---

###### Page 19

Page **19**  of **42** 



### AMPHETAMINE/DEXTROAMPHETAMINE SALTS 12.5MG TABLET 

29008  



**Step** **6** **(amphetamine** **salts** **immediate** **release** **tablets,** **dextroamphetamine** **immediate** **release** 

**tablets,** **dexmethylphenidate,** **methylphenidate,** **Procentra,** **or** **Zenzedi)**  

**Required** **quantity:** *1* 

**Label** **Name** **GCN**  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG TABLET 

### 29009  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG TABLET 

### 56973  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG TABLET 

### 56972  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG TABLET 

### 56970  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 7.5MG TABLET 

29007  DEXMETHYLPHENIDATE 10MG TABLET 14975 DEXMETHYLPHENIDATE 2.5MG TABLET 14973 DEXMETHYLPHENIDATE 5MG TABLET 14974 DEXTROAMPHETAMINE 10MG TABLET 19880 DEXTROAMPHETAMINE 5MG TABLET 19881 DEXTROAMPHETAMINE 5MG/5ML SOLUTION 99801 EVEKEO 10MG TABLET 19821 EVEKEO 5MG TABLET 19822 EVEKEO ODT 10MG 45977 EVEKEO ODT 15MG 45978 EVEKEO ODT 20MG 45979 EVEKEO ODT 5MG 45976 FOCALIN 10MG TABLET 14975 FOCALIN 2.5MG TABLET 14973 FOCALIN 5MG TABLET 14974 METHYLIN 10MG/5ML SOLUTION 22686 METHYLIN 5MG/5ML SOLUTION 22685 METHYLPHENIDATE 10 MG CHEW TB 22684 METHYLPHENIDATE 10MG TABLET 15911 METHYLPHENIDATE 10MG/5ML SOL 22686 METHYLPHENIDATE 2.5 MG CHEW TB 22682 METHYLPHENIDATE 20MG TABLET 15920 METHYLPHENIDATE 5 MG CHEW TB 22683 METHYLPHENIDATE 5MG TABLET 15913 METHYLPHENIDATE 5MG/5ML SOLUTION 22685 PROCENTRA 5MG/5ML SOLUTION 99801 RITALIN 10MG TABLET 15911 


---

###### Page 20

Page **20**  of **42** 



### RITALIN 20MG TABLET 15920 RITALIN 5MG TABLET 15913 ZENZEDI 10MG TABLET 19880 



**Step** **6** **(amphetamine** **salts** **immediate** **release** **tablets,** **dextroamphetamine** **immediate** **release** 

**tablets,** **dexmethylphenidate,** **methylphenidate,** **Procentra,** **or** **Zenzedi)**  

**Label** **Name** **GCN**  ZENZEDI 15MG TABLET 19885 ZENZEDI 2.5MG TABLET 34734 ZENZEDI 20MG TABLET 36463 ZENZEDI 30MG TABLET 36464 ZENZEDI 5MG TABLET 19881 ZENZEDI 7.5MG TABLET 34735 



**ADD/ADHD**  **Diagnoses** **ICD-10** **Code** **Description** **F900** 

**Narcolepsy** **Diagnoses** 

 

**Required** **quantity:** *1* 

**Step**  **8** **(diagnosis** **of** **ADD** **or** **ADHD)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *730* *days* 

### **ATTENTION-DEFICIT** **HYPERACTIVITY** **DISORDER,** **PREDOMINANTLY** **INATTENTIVE** **TYPE** **F901** 

### **ATTENTION-DEFICIT** **HYPERACTIVITY** **DISORDER,** **PREDOMINANTLY** **HYPERACTIVE** **TYPE** **F902** **ATTENTION-DEFICIT** **HYPERACTIVITY** **DISORDER,** **COMBINED** **TYPE** **F908** **ATTENTION-DEFICIT** **HYPERACTIVITY** **DISORDER,** **OTHER** **TYPE** **F909** **ATTENTION-DEFICIT** **HYPERACTIVITY** **DISORDER,** **UNSPECIFIED** **TYPE** 



**Step**  **9** **(diagnosis** **of** **narcolepsy)** 

**Required** **diagnosis:** *1* **Look** **back** **timeframe:** *730* *days* 


---

###### Page 21

Page **21**  of **42** 



**Step**  **9** **(diagnosis** **of** **narcolepsy)** 

**Required** **diagnosis:** *1* **Look** **back** **timeframe:** *730* *days* 

**Narcolepsy** **Diagnoses** **ICD-10** **Code** **Description** **G47419** **NARCOLEPSY** **WITHOUT** **CATAPLEXY** **G47411** **NARCOLEPSY** **WITH** **CATAPLEXY** **G47429** 

### **NARCOLEPSY** **IN** **CONDITIONS** **CLASSIFIED** **ELSEWHERE** **WITHOUT** **CATAPLEXY** **G47421** 

### **NARCOLEPSY** **IN** **CONDITIONS** **CLASSIFIED** **ELSEWHERE** **WITH** **CATAPLEXY** 



**Step** **10** **(dexmethylphenidate** **immediate** **release, Evekeo ODT** **or** **methamphetamine)** 

**Required** **quantity:** *1* **Dexmethylphenidate** **Immediate** **Release** **Drugs/Methamphetamines** **Label** **Name** **GCN**  DESOXYN 5MG TABLET 19932 DEXMETHYLPHENIDATE 2.5MG TABLET 14973 DEXMETHYLPHENIDATE 5MG TABLET 14974 DEXMETHYLPHENIDATE 10MG TABLET 14975 EVEKEO ODT 10MG 45977 EVEKEO ODT 15MG 45978 EVEKEO ODT 20MG 45979 EVEKEO ODT 5MG 45976 FOCALIN 2.5MG TABLET 14973 FOCALIN 5MG TABLET 14974 FOCALIN 10MG TABLET 14975 METHAMPHETAMINE 5MG TABLET 19932 



 


---

###### Page 22

Page **22**  of **42** 



## **Drugs Requiring Prior Authorization-** **ER Formulations:** The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search. 





**Drugs** **Requiring** **Prior** **Authorization** **Label** **Name** **GCN**  ADDERALL XR 10MG CAPSULE 14635 ADDERALL XR 15MG CAPSULE 17468 ADDERALL XR 20MG CAPSULE 14636 ADDERALL XR 25MG CAPSULE 17469 ADDERALL XR 30MG CAPSULE 14637 ADDERALL XR 5MG CAPSULE 17459 ADHANSIA XR 25MG CAPSULE 44356 ADHANSIA XR 35MG CAPSULE 44358 ADHANSIA XR 45MG CAPSULE 44362 ADHANSIA XR 55MG CAPSULE 44363 ADHANSIA XR 70MG CAPSULE 44364 ADHANSIA XR 85MG CAPSULE 44365 ADZENYS ER 1.25 MG/ML SUSP

43864 ADZENYS XR-ODT 3.1MG TABLET 40647 ADZENYS XR-ODT 6.3MG TABLET 40648 ADZENYS XR-ODT 12.5MG TABLET 40650 ADZENYS XR-ODT 15.7MG TABLET 40653 ADZENYS XR-ODT 18.8MG TABLET 40654 AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG EXTENDED-RELEASE CAPSULE 

### 14635  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG EXTENDED-RELEASE CAPSULE 

### 17468  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG EXTENDED-RELEASE CAPSULE 

### 14636  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 25MG EXTENDED-RELEASE CAPSULE 

### 17469  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG EXTENDED-RELEASE CAPSULE 

### 14637  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG EXTENDED-RELEASE CAPSULE 

17459  APTENSIO XR 10MG CAPSULE 97234 APTENSIO XR 15MG CAPSULE 97235 APTENSIO XR 20MG CAPSULE 97236 APTENSIO XR 30MG CAPSULE 97237 APTENSIO XR 40MG CAPSULE 97238 APTENSIO XR 50MG CAPSULE 97239 


---

###### Page 23

Page **23**  of **42** 



APTENSIO XR 60MG CAPSULE 97240 CONCERTA ER 18MG TABLET 12567 CONCERTA ER 27MG TABLET 17123 CONCERTA ER 36MG TABLET 12568 



 


---

###### Page 24

Page **24**  of **42** 



**Drugs** **Requiring** **Prior** **Authorization** **Label** **Name** **GCN**  CONCERTA ER 54MG TABLET 12248 COTEMPLA XR-ODT 17.3MG TABLET 43535 COTEMPLA XR-ODT 25.9MG TABLET 43536 COTEMPLA XR-ODT 8.6MG TABLET 43534 DAYTRANA 10MG/9HR PATCH 26801 DAYTRANA 15MG/9HR PATCH 26802 DAYTRANA 20MG/9HR PATCH 26803 DAYTRANA 30MG/9HR PATCH 26804 DEXEDRINE SPANSULE 10MG 19850 DEXEDRINE SPANSULE 15MG 19851 DEXEDRINE SPANSULE 5MG 19852 DEXMETHYLPHENIDATE 10MG EXTENDED RELEASE

CAPSULE 

### 24734  DEXMETHYLPHENIDATE 15MG EXTENDED RELEASE CAPSULE 

### 97111  DEXMETHYLPHENIDATE 20MG EXTENDED RELEASE CAPSULE 

### 24735  DEXMETHYLPHENIDATE 25MG EXTENDED RELEASE CAPSULE 

### 30305  DEXMETHYLPHENIDATE 30MG EXTENDED RELEASE CAPSULE 

### 28035  DEXMETHYLPHENIDATE 35MG EXTENDED RELEASE CAPSULE 

### 30306  DEXMETHYLPHENIDATE 40MG EXTENDED RELEASE CAPSULE 

### 28933  DEXMETHYLPHENIDATE 5MG EXTENDED RELEASE CAPSULE 

### 24733  DEXTROAMPHETAMINE 10MG EXTENDEDRELEASE CAPSULE 

### 19850  DEXTROAMPHETAMINE 15MG EXTENDEDRELEASE CAPSULE 

### 19851  DEXTROAMPHETAMINE 5MG EXTENDEDRELEASE CAPSULE 

19852  DYANAVEL XR 2.5MG/ML SUSP 39686 FOCALIN XR 10MG CAPSULE 24734 FOCALIN XR 15MG CAPSULE 97111 FOCALIN XR 20MG CAPSULE 24735 FOCALIN XR 25MG CAPSULE 30305 FOCALIN XR 30MG CAPSULE 28035 FOCALIN XR 35MG CAPSULE 30306 FOCALIN XR 40MG CAPSULE 28933 FOCALIN XR 5MG CAPSULE 24733 JORNAY PM 100 MG CAPSULE 45110 JORNAY PM 20 MG CAPSULE 45106 


---

###### Page 25

Page **25**  of **42** 



### JORNAY PM 40 MG CAPSULE 45107 JORNAY PM 60 MG CAPSULE 45108 JORNAY PM 80 MG CAPSULE 45109 



**Drugs** **Requiring** **Prior** **Authorization** **Label** **Name** **GCN**  METADATE

ER 20MG TABLET ER 16180 METHYLPHENIDATE 10MG EXTENDEDRELEASE CAPSULE 

### 21763  METHYLPHENIDATE 18MG EXTENDEDRELEASE TABLET 

### 12567  METHYLPHENIDATE 20MG EXTENDEDRELEASE CAPSULE 

### 20387  METHYLPHENIDATE 20MG SUSTAINEDRELEASE TABLET 

### 16180  METHYLPHENIDATE 27MG EXTENDEDRELEASE TABLET 

### 17123  METHYLPHENIDATE 30MG EXTENDEDRELEASE CAPSULE 

### 20388  METHYLPHENIDATE 36MG EXTENDEDRELEASE TABLET 

### 12568  METHYLPHENIDATE 40MG EXTENDEDRELEASE CAPSULE 

### 20391  METHYLPHENIDATE 54MG EXTENDEDRELEASE TABLET 

### 12248  METHYLPHENIDATE 60MG EXTENDEDRELEASE CAPSULE 

### 36195  METHYLPHENIDATE 72 MG EXTENDEDRELEASE TABLET 

### 44239  METHYLPHENIDATE CD 10MG EXTENDEDRELEASE CAPSULE 

### 20384  METHYLPHENIDATE CD 20MG EXTENDEDRELEASE

CAPSULE 

### 20385  METHYLPHENIDATE CD 30MG EXTENDEDRELEASE CAPSULE 

### 20386  METHYLPHENIDATE CD 40MG EXTENDEDRELEASE CAPSULE 

### 26734  METHYLPHENIDATE CD 50MG EXTENDEDRELEASE CAPSULE 

### 26735  METHYLPHENIDATE CD 60MG EXTENDEDRELEASE

CAPSULE 

26736  METHYLPHENIDATE

ER 10 MG TAB 93075 MYDAYIS ER 12.5 MG CAPSULE 43538 MYDAYIS ER 25 MG CAPSULE 43539 MYDAYIS ER 37.5 MG CAPSULE 43542 MYDAYIS ER 50 MG CAPSULE 43543 QUILLICHEW ER 20MG CHEW TAB 40289 QUILLICHEW ER 30MG CHEW TAB 40292 QUILLICHEW ER 40MG CHEW TAB 40293 


---

###### Page 26

Page **26**  of **42** 



### QUILLIVANT XR 25MG/5ML SUSP 33887 RITALIN LA 10MG CAPSULE 21763 RITALIN LA 20MG CAPSULE 20387 RITALIN LA 30MG CAPSULE 20388 RITALIN LA 40MG CAPSULE 20391 



**Drugs** **Requiring** **Prior** **Authorization** **Label** **Name** **GCN**  VYVANSE 10MG CAPSULE 37674 VYVANSE 10MG CHEWABLE TABLET 42969 VYVANSE 20MG CAPSULE 99366 VYVANSE 20MG CHEWABLE TABLET 43058 VYVANSE 30MG CAPSULE 98071 VYVANSE 30MG CHEWABLE TABLET 43059 VYVANSE 40MG CAPSULE 99367 VYVANSE 40MG CHEWABLE TABLET 43063 VYVANSE 50MG CAPSULE 98072 VYVANSE 50MG CHEWABLE TABLET 43064 VYVANSE 60MG CAPSULE 99368 VYVANSE 60MG CHEWABLE TABLET 43065 VYVANSE 70MG CAPSULE 98073 



 


---

###### Page 27

Page **27**  of **42** 



## **Superior HealthPlan** **Clinical Edit Logic Diagram-** **ER Formulations:** 

![SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_27_86](Generated/images/SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_27_86.png)


---

###### Page 28

Page **28**  of **42** 



## **Supporting Tables-** **ER Formulation Step Logic:**  



##### For the list of diagnosis codes that pertain to this step, see the **History of** **Substance** **Abuse** 

##### **Diagnoses**  table in the previous “Supporting Tables” section. 







**Step** **2** **(history** **of** **substance** **abuse)** 

**Required** **quantity:** *1* 

**Look** **back** **timeframe:** *365* *days* 


---

###### Page 29

Page **29**  of **42** 



**Step** **3** **(Texas** **DFPS** **maximum** **recommended** **dose)** **Required** **quantity:** *1* 

**TX**  **DFPS** **Recommended** **Dosage** 



**Active** **Ingredient** 

**Drug** **(brand)** 

### AMPHETAMINE SALTS 

### MYDAYIS™ 

ADDERALL<sup>® </sup> XR  

### AMPHETAMINE/ DEXTROAMPHETAMINE

SALTS 

### DYANAVEL™ XR 

### AMPHETAMINE/ DEXTROAMPHETAMINE

SALTS 

### ADZENYS XR-ODT™ 

### DEXMETHYLPHENIDATE 

FOCALIN<sup>® </sup> XR  

### DEXTROAMPHETAMINE 

### LISDEXAMFETAMINE 

### METHYLPHENIDATE 

ADHANSIA XR™ Age ≥ 6 years: 

APTENSIO XR<sup>®</sup> Age ≥ 6 years: 10 

<sup></sup>

**Initial** **Dosage** 

VYVANSE<sup>®</sup> capsule VYVANSE<sup>® </sup> chewable

tablet 

25mg/day 

mg/day 

**Literature** **Based** **Maximum** **Dosage** 

FDA  Approved Maximum Dosage for Children and Adolescents 



Age 13-17 years: 12.5mg/day 

Age ≥13 years: 25mg/day 

≥  6  years: 20mg/day 

Age ≥ 6 years: 50mg/day 

DEXEDRINE SPANSULE<sup>® </sup> 

Age ≥ 6 years: 70mg/day 

METADATE<sup>®</sup> CD QUILLICHEW ER™ QUILLIVANT XR<sup>® </sup> 

<sup></sup>



METADATE<sup>® </sup> ER  METHYLIN<sup>®</sup> ER  RITALIN<sup>® </sup> SR  

50kg:  100mg/day 

Age  13 -17 years: 

25mg Age  >  17 years: 50mg AMPHETAMINE/ DEXTROAMPHETAMINE

SALTS 

Age  6-12 years: 5-10mg/day  Age ≥ 13 years: 

Age ≥ 6 years (≤ 50kg): 30mg/day Age ≥ 6 years (> 50kg): 60mg/day 

Approved for children 6 years and

older: 30mg/day 

Age  ≥ 6 years: 2.5– 5mg/day 

Approved  for children 6 years and

older: 20mg/day 

Age  6-17 years: 6.3mg/day 

Age 6-12 years: 18.8mg daily  Age 13-17 years: 12.5mg daily  

Age 6-12 years: 18.8mg daily  Age 13-17 years: 12.5mg daily 

Age  ≥ 6 years: 510mg/day 

Approved  for children 6 years and

older: 30mg/day 



Age  ≥ 6 years: 5mg/day 

Age ≥ 6 years (≤ 50kg): 40mg/day Age ≥ 6 years (> 50kg): 60mg/day 

Approved for children 6 years and

older: 40mg/day 

Age  ≥ 6 years: 30mg/day 

Approved  for children 6 years and

older: 70mg/day 









Age 6-17 years:85mg/day Age ≥18 years: 100mg/day 

Age 6-17 years:85mg/day Age ≥18 years: 100mg/day 

Age 3-5 years: 22.5mg/day Age ≥ 6 years  and ≤ 50kg: 60mg/day Age ≥ 6 years  and > 50kg: 100mg/day 

Approved for children 6 years and

older: 60mg/day 

Age ≥ 6 years: 20mg/day 

Age 3-5 years: 22.5mg/day Age ≥ 6 years (≤ 50kg): 60mg/day Age ≥ 6 years (> 

Approved for children 6 years and older: 60mg/day 

Age ≥ 3 years: 10mg/day 

Age 3-5 years: 22.5mg/day Age ≥ 6 years and ≤ 50kg: 60mg/day Age ≥ 6 years and > 

Approved for children 6 years and

older: 60mg/day 


---

###### Page 30

Page **30**  of **42** 



### CONCERTA® 

### COTEMPLA® XR-ODT 

### DAYTRANA® TD 

### RITALIN® LA 

### JORNAY PM™ 

Age ≥ 6 years: 18mg/day 

Age 3-5 years: 36mg/day Age ≥ 6 years: 72mg/day 

Age 6-12 years: 54mg/day Age 13- 17 years: lesser of 72mg/day or 2mg/kg/day 

Age ≥ 6 years: 17.3mg/day 

Age 6-17 years: 51.8mg/day 

Approved for children 6 years and older: 51.8mg/day 

Age ≥ 6 years: 10mg/day 

Age 3-5 years: 20mg/day Age ≥ 6 years: 30mg/day 

Approved for children 6 years and older: 30mg/day 

Age ≥ 6 years: 10 20mg/day 

Age 3-5 years: 22.5mg/day Age ≥ 6 years (≤ 50kg): 60mg/day 

Age ≥ 6 years (> 50kg): 

Approved for children 6 years and older: 60mg/day 

Age ≥ 6 years: 20mg/day 

Age ≥ 6 years: 100mg/day 

Age ≥ 6 years: 100mg/day 


---

###### Page 31

Page **31**  of **42** 



**S** **tep** **4** **(paid** **claim** **for** **another** **ER** **stimulant)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *14* *days* 

**ER**  **Stimulants** **Label** **Name** **GCN**  ADDERALL XR 10MG CAPSULE 14635 ADDERALL XR 15MG CAPSULE 17468 ADDERALL XR 20MG CAPSULE 14636 ADDERALL XR 25MG CAPSULE 17469 ADDERALL XR 30MG CAPSULE 14637 ADDERALL XR 5MG CAPSULE 17459 ADHANSIA XR 25MG CAPSULE 44356 ADHANSIA XR 35MG CAPSULE 44358 ADHANSIA XR 45MG CAPSULE 44362 ADHANSIA XR 55MG CAPSULE 44363 ADHANSIA XR 70MG CAPSULE 44364 ADHANSIA XR 85MG CAPSULE 44365 ADZENYS ER 1.25 MG/ML SUSP 43864 ADZENYS XR-ODT 3.1MG TABLET 40647 ADZENYS XR-ODT 6.3MG TABLET 40648 ADZENYS XR-ODT 9.4MG TABLET 40649 ADZENYS XR-ODT 12.5MG TABLET 40650 ADZENYS XR-ODT 15.7MG TABLET 40653 ADZENYS XR-ODT 18.8MG TABLET 40654 AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG EXTENDED-RELEASE CAPSULE 

### 14635  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG EXTENDED-RELEASE CAPSULE 

### 17468  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG EXTENDED-RELEASE CAPSULE 

### 14636  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 25MG EXTENDED-RELEASE CAPSULE 

### 17469  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG EXTENDED-RELEASE CAPSULE 

### 14637  AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG EXTENDED-RELEASE CAPSULE 

### 17459  APTENSIO XR 10MG CAPSULE 97234 APTENSIO XR 15MG CAPSULE 97235 APTENSIO XR 20MG CAPSULE 97236 APTENSIO XR 30MG CAPSULE 97237 APTENSIO XR 40MG CAPSULE 97238 APTENSIO XR 50MG CAPSULE 97239 APTENSIO XR 60MG CAPSULE 97240 

CONCERTA ER 18MG TABLET 12567 CONCERTA ER 27MG TABLET 17123 


---

###### Page 32

Page **32**  of **42** 



### CONCERTA ER 36MG TABLET 12568 CONCERTA ER 54MG TABLET 12248 COTEMPLA

XR-ODT 17.3MG TABLET 43535 COTEMPLA XR-ODT 25.9MG TABLET 43536 COTEMPLA

XR-ODT 8.6MG TABLET 43534 



**Step** **4** **(paid** **claim** **for** **another** **ER** **stimulant)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *14* *days* 

**ER**  **Stimulants** **Label** **Name** **GCN**  DAYTRANA 10MG/9HR PATCH 26801 DAYTRANA 15MG/9HR PATCH 26802 DAYTRANA 20MG/9HR PATCH 26803 DAYTRANA 30MG/9HR PATCH 26804 DEXEDRINE SPANSULE 10MG 19850 DEXEDRINE SPANSULE 15MG 19851 DEXEDRINE SPANSULE 5MG 19852 DEXMETHYLPHENIDATE 10MG EXTENDED RELEASE CAPSULE 

### 24734  DEXMETHYLPHENIDATE 15MG EXTENDED RELEASE CAPSULE 

### 97111  DEXMETHYLPHENIDATE 20MG EXTENDED RELEASE CAPSULE 

### 24735  DEXMETHYLPHENIDATE 25MG EXTENDED RELEASE CAPSULE 

### 30305  DEXMETHYLPHENIDATE 30MG EXTENDED RELEASE CAPSULE 

### 28035  DEXMETHYLPHENIDATE 35MG EXTENDED RELEASE CAPSULE 

### 30306  DEXMETHYLPHENIDATE 40MG EXTENDED RELEASE CAPSULE 

### 28933  DEXMETHYLPHENIDATE 5MG EXTENDED RELEASE CAPSULE 

### 24733  DEXTROAMPHETAMINE 10MG EXTENDEDRELEASE CAPSULE 

### 19850  DEXTROAMPHETAMINE 15MG EXTENDEDRELEASE

CAPSULE 

### 19851  DEXTROAMPHETAMINE 5MG EXTENDEDRELEASE CAPSULE 

19852  DYANAVEL 2.5MG/ML SUSP 39686 FOCALIN XR 10MG CAPSULE 24734 FOCALIN XR 15MG CAPSULE 97111 FOCALIN XR 20MG CAPSULE 24735 FOCALIN XR 25MG CAPSULE 30305 FOCALIN XR 30MG CAPSULE 28035 FOCALIN XR 35MG CAPSULE 30306 


---

###### Page 33

Page **33**  of **42** 



### FOCALIN XR 40MG CAPSULE 28933 FOCALIN XR 5MG CAPSULE 24733 JORNAY PM 100 MG CAPSULE 45110 JORNAY PM 20 MG CAPSULE 45106 JORNAY PM 40 MG CAPSULE 45107 JORNAY PM 60 MG CAPSULE 45108 JORNAY PM 80 MG CAPSULE 45109 



**Step** **4** **(paid** **claim** **for** **another** **ER** **stimulant)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *14* *days* 

**ER**  **Stimulants** **Label** **Name** **GCN**  METADATE ER 20MG TABLET ER 16180 METHYLPHENIDATE 10MG EXTENDEDRELEASE CAPSULE 

### 21763  METHYLPHENIDATE 18MG EXTENDEDRELEASE TABLET 

### 12567  METHYLPHENIDATE 20MG EXTENDEDRELEASE CAPSULE 

### 20387  METHYLPHENDIATE 20MG EXTENDEDRELEASE TABLET 

### 16180  METHYLPHENIDATE 27MG EXTENDEDRELEASE TABLET 

### 17123  METHYLPHENIDATE 30MG EXTENDEDRELEASE CAPSULE 

### 20388  METHYLPHENIDATE 36MG EXTENDEDRELEASE TABLET 

### 12568  METHYLPHENIDATE 40MG EXTENDEDRELEASE CAPSULE 

### 20391  METHYLPHENIDATE 54MG EXTENDEDRELEASE TABLET 

### 12248  METHYLPHENIDATE 60MG EXTENDEDRELEASE CAPSULE 

### 36195  METHYLPHENIDATE 72 MG EXTENDEDRELEASE TABLET 

### 44239  METHYLPHENIDATE CD 10MG EXTENDEDRELEASE CAPSULE 

### 20384  METHYLPHENIDATE CD 20MG EXTENDEDRELEASE CAPSULE 

### 20385  METHYLPHENIDATE CD 30MG EXTENDEDRELEASE CAPSULE 

### 20386  METHYLPHENIDATE CD 40MG EXTENDEDRELEASE CAPSULE 

### 26734  METHYLPHENIDATE CD 50MG EXTENDEDRELEASE CAPSULE 

### 26735  METHYLPHENIDATE CD 60MG EXTENDEDRELEASE

CAPSULE 

26736  METHYLPHENIDATE

ER 10 MG TAB 93075 


---

###### Page 34

Page **34**  of **42** 



### MYDAYIS ER 12.5 MG CAPSULE 43538 MYDAYIS ER 25 MG CAPSULE 43539 MYDAYIS ER 37.5 MG CAPSULE 43542 MYDAYIS ER 50 MG CAPSULE 43543 

### QUILLICHEW ER 20MG CHEW TAB 40289 QUILLICHEW ER 30MG CHEW TAB 40292 QUILLICHEW ER 40MG CHEW TAB 40293 QUILLIVANT XR 25MG/5ML SUSP 33887 RITALIN LA 10MG CAPSULE 21763 RITALIN LA 20MG CAPSULE 20387 RITALIN LA 30MG CAPSULE 20388 RITALIN LA 40MG CAPSULE 20391 



**Step** **4** **(paid** **claim** **for** **another** **ER** **stimulant)** 

**Required** **quantity:** *1* **Look** **back** **timeframe:** *14* *days* 

**ER**  **Stimulants** **Label** **Name** **GCN**  VYVANSE 10MG CAPSULE 37674 VYVANSE 10MG CHEWABLE TABLET 42969 VYVANSE 20MG CAPSULE 99366 VYVANSE 20MG CHEWABLE TABLET 43058 VYVANSE 30MG CAPSULE 98071 VYVANSE 30MG CHEWABLE TABLET 43059 VYVANSE 40MG CAPSULE 99367 VYVANSE 40MG CHEWABLE TABLET 43063 VYVANSE 50MG CAPSULE 98072 VYVANSE 50MG CHEWABLE TABLET 43064 VYVANSE 60MG CAPSULE 99368 VYVANSE 60MG CHEWABLE TABLET 43065 VYVANSE 70MG CAPSULE 98073 



## For the list of diagnoses that pertain to this step, see the **ADD/ADHD** **Diagnoses** table

in the previous “Supporting Tables” section. 



**Step** **6** **(diagnosis** **of** **ADD** **or** **ADHD)** 

**Required** **quantity:** *1* 

**Look** **back** **timeframe:** *730* *days* 


---

###### Page 35

Page **35**  of **42** 



## For the list of diagnoses that pertain to this step, see the **Narcolepsy Diagnoses** table

in the previous “Supporting Tables” section. 

## **Step** **8** **(methylphenidate** **extended** **release** **tablets,** **methylphenidate** **sustained** **release** **tablets,** 

**or**  **dextroamphetamine** **extended** **release** **capsules)** 

**Required** **quantity:** *1* **Label** **Name** **GCN**  DEXTROAMPHETAMINE 5MG EXTENDEDRELEASE CAPSULE 

### 19852  DEXTROAMPHETAMINE 10MG EXTENDEDRELEASE CAPSULE 

### 19850  DEXTROAMPHETAMINE 15MG EXTENDEDRELEASE CAPSULE 

### 19851  METADATE ER 20MG TABLET ER 

### 16180  METHYLPHENIDATE 20MG SUSTAINEDRELEASE TABLET 

### 16180  METHYLPHENIDATE ER 10 MG TAB 93075 

**Step** **7** **(diagnosis** **of** **narcolepsy)** 

**Required** **diagnosis:** *1* 

**Look** **back** **timeframe:** *730* *days* 


---

###### Page 36

Page **36**  of **42** 



## **Drugs Requiring Prior Authorization-** **Non-stimulant Formulations** **(Except** **Clonidine ER):** 



**Drugs** **Requiring** **Prior** **Authorization** **Label** **Name** **GCN**  ATOMOXETINE HCL 100MG CAPSULE 26539 ATOMOXETINE HCL 10MG CAPSULE 18776 ATOMOXETINE HCL 18MG CAPSULE 18777 ATOMOXETINE HCL 25MG CAPSULE 18778 ATOMOXETINE HCL 40MG CAPSULE 18779 ATOMOXETINE HCL 60MG CAPSULE 18781 ATOMOXETINE HCL 80MG CAPSULE 26538 GUANFACINE HCL ER 1MG TABLET 27576 GUANFACINE HCL ER 2MG TABLET 27578 GUANFACINE HCL ER 3MG TABLET 27579 GUANFACINE HCL ER 4MG TABLET 27582 INTUNIV ER 1MG TABLET 27576 INTUNIV ER 2MG TABLET 27578 INTUNIV ER 3MG TABLET 27579 INTUNIV ER 4MG TABLET 27582 STRATTERA 100MG CAPSULE 26539 STRATTERA 10MG CAPSULE 18776 STRATTERA 18MG CAPSULE 18777 STRATTERA 25MG CAPSULE 18778 STRATTERA 40MG CAPSULE 18779 STRATTERA

60MG CAPSULE 18781 STRATTERA 80MG CAPSULE 26538 



 


---

###### Page 37

Page **37**  of **42** 



## **Superior HealthPlan Clinical Edit Logic Diagram** **-** **Non-stimulant** **Formulations (Except Clonidine ER)** **:** 

### 

**Supporting Tables** **-** **Non-stimulant Formulations (Except Clonidine** **ER):** 



For the list of diagnoses that pertain to this step, please see the **ADD/ADHD** **Diagnoses** table in 

![SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_37_308](Generated/images/SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_37_308.png)

a previous “Supporting Tables” section. 



 

**Step** **4** **(diagnosis** **of** **ADD** **or** **ADHD)** 

**Required** **quantity:** *1* 

**Look**  **back** **timeframe:** *730* *days* 


---

###### Page 38

Page **38**  of **42** 



## **Drugs Requiring Prior Authorization-** **Clonidine ER:** 



**Drugs** **Requiring** **Prior** **Authorization** **Label** **Name** **GCN**  CLONIDINE HCL ER 0.1MG TABLET 29139 



**Superior HealthPlan Clinical Edit Logic Diagram-** **Clonidine ER:** 



## 

**Supporting Tables-** **Clonidine ER:** 



For the list of diagnoses that pertain to this step, please see the **ADD/ADHD** **Diagnoses** table in 

![SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_38_564](Generated/images/SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_38_564.png)

![SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_38_621](Generated/images/SHP_20205921-Superior-ADD-ADHD-Amended-Clinical-Edit-P-02242020_38_621.png)

a previous “Supporting Tables” section. 

 

**Step** **4** **(diagnosis** **of** **ADD** **or** **ADHD)**

**Required** **quantity:** *1* 

**Look** **back** **timeframe:** *730* *days* 


---

###### Page 39

Page **39**  of **42** 



## **Clinical Edit References:**  



1. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; 2015. Available at www.clinicalpharmacology.com. Accessed on March 4, 2016.  

2. Micromedex [online database]. Available at www.micromedexsolutions.com. Accessed on March 4, 201 6.  

3. The American Academy of Pediatrics. Implementing the key action statements: An algorithm and explanation for process of care for the evaluation, diagnosis, treatment and monitoring of ADHD in children and adolescents. November 1, 2011. Available at **ht** **tp://pediatrics.aappublications.org/content/suppl/2011/10/11/peds.2011-** **2654.DC1/zpe611117822p.pdf**.  

4. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN Report: Emergency department visits involving attention deficit/hyperactivity disorder stimulant medications*.* Rockville, MD*.* January 24, 2013.  

5. Texas Health and Human Services. Psychotropic Medication Utilization Parameters for Children and Youth in Texas Public Behavioral Health (6th version). Developed by The Parameters Workgroup of the Psychiatric Executive Formulary Committee, Health and Specialty Care Division, Texas Health and Human Services Commission. Review and Input provided by The University of Texas at Austin College of Pharmacy, The UT System Medical Schools, Texas A&M Health Science Center and Texas Tech University Health Sciences Center. June 2019. 

6. 2015 ICD-9-CM Diagnosis Codes. 2015. Available at **www.icd9data.com**. Accessed on April 3, 2015.  

7. 2015 ICD-10-CM Diagnosis Codes. 2015. Available at **www.icd10data.com**. Accessed on April 3, 2015.  

8. American Medical Association data files. 2015 ICD-9-CM Diagnosis Codes. Available at **www.commerce.ama** **-assn.org**.  

9. American Medical Association data files. 2015 ICD-10-CM Diagnosis Codes. Available at **www.commerce.ama** **-assn.org**.  

10. Aptensio XR Prescribing Information. Coventry, RI. Rhodes Pharmaceuticals L.P. April 2015.  

11. Concerta Prescribing Information. Titusville, NJ. Janssen Pharmaceuticals, Inc. December 2013.  

12. Daytrana Prescribing Information. Miami, FL. Noven Therapeutics, LLC. August 2015.  

13. Evekeo Prescribing Information. Atlanta, GA. Arbor Pharmaceuticals, LLC. May 2015.  

14. Evekeo ODT Prescribing Information. Atlanta, GA. Arbor Pharmaceuticals, LLC. March 2019. 

15. Focalin Prescribing Information. East Hanover, NJ. Novartis Pharmaceuticals Corporation. April 2015.  

16. Focalin XR Prescribing Information. East Hanover, NJ. Novartis Pharmaceuticals Corporation. June 2015.  

17. Intuniv Prescribing Information. Lexington, MA. Shire US Inc. December 2015.  

18. Ritalin and Ritalin-SR Prescribing Information. East Hanover, NJ. Novartis Pharmaceuticals Corporation. April 2015.  




---

###### Page 40

Page **40**  of **42** 



19. Ritalin LA Prescribing Information. East Hanover, NJ. Novartis Pharmaceuticals Corporation. July 

2015.  

20. Quillichew ER Prescribing Information. New York, NY. Pfizer, Inc. December 2015.  

21. Quillivant XR Prescribing Information. New York, NY. Pfizer, Inc. February 2015.  

22. Strattera Prescribing Information. Indianapolis, IN. Eli Lilly and Company. April 2015.  

23. Vyvanse Prescribing Information. Lexington, MA. Shire US Inc. April 2017.  

24. Zenzedi Prescribing Information. Atlanta, GA. Arbor Pharmaceuticals, LLC. January 2014.  



25. Adzenys XR-ODT Prescribing Information. Grand Prairie, TX. Neos Therapeutics, Inc. January 2016.  



26. Mydayis Prescribing Information. Lexington, MA. Shire US Inc. June 2017.  



27. Cotempla Prescribing Information. Grand Prairie, TX. Neos Therapeutics, Inc. June 2017.  

28. Jornay PM Prescribing Information. Cherry Hill, NJ. Ironshore Pharmaceuticals Inc. April 2019. 

29. Adhansia Prescribing Information. Wilson, NC. Purdue Pharma L.P. July 2019. 




---

###### Page 41

Page **41**  of **42** 



## **Publication History:** 



**Publication**  

**Date** 

**Notes** 

03/09/2015 Clinical edit added, updated per VDP publication history on main edit cross reference. 07/04/2018 The age limit for all IR and ER stimulants has been lowered from 6 years of age to 3 years of age , which eases PA requirement. Reference tables, diagnosis codes, references and publication table per UMCM Chapter 3 requirements. All tables are cross referenced to VDP criteria. 

05/20/2019 Removed Methylin chewable tablets from “Drugs Requiring PA” as product is no longer eligible for CMS rebates 

Removed drugs not specifically indicated for narcolepsy from table 8 (including: Aptensio XR, Concerta, Daytrana, Quillichew, Quillivant, Ritalin LA and associated generic products) 

Added statement that this criteria applies to CHIP, STAR, STAR Kids, STAR Health

and STAR+PLUS membership. 

Added statement: The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formula ry/formulary-search. 

10/1/2019 Updated dosing guidelines to reflect the Psychotropic Medication Utilization Parameters for Children and Youth in Texas Public Behavioral Health (6th Version). 

Added GCNs for Jornay PM, dexmethylphenidate 25mg and 35mg extended

release capsules, methylphenidate 60mg and 72mg extended

release capsules, methylphenidate 10mg extended release capsule s, Adzenys ER 1.25 mg/ml susp and removed Metadate CD from Drugs Requiring Prior Authorization: ER Formulations. 

Cross referenced tables and references to VDP criteria. Updated references, tables for step 4

(ER Formulations), step 6, step 8, and step 9 


---

###### Page 42

Page **42**  of **42** 



1/25/20 

Added GCNs for Evekeo ODT to drug tables in IR Formulations 

Updated IR formulations criteria logic and diagram to include Evekeo tablets for ages ≥ 3 and up and narcolepsy as an approvable diagnosis 

Added GCNs for Adhansia XR to drug tables in ER Formulations. 

2/7/20 

Updated IR formulations criteria chart to match P&T approved changes to step 5 and step 6 


### Footnotes
